drugset / Trial / NCT04757610
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Timeline
- Start
- 2021-03-12
- Primary completion
- 2025-03-31
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | SOZINIBERCEPT | Protein / enzyme biologic | 2 mg | Intravitreal |